Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back pain
MESO•Phase 3 dosing completed, top-line readout due in mid-2027
Mesoblast completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease.
Top-line results have not been presented yet; the 12-month readout is expected in mid-2027.
The study is designed to confirm durable pain relief versus a sham procedure, with additional focus on function and reduced pain-medication use.
Management framed the program as a potential blockbuster, citing a U.S. patient pool of more than 7 million.
The drug holds FDA RMAT designation, positioning it for priority review once a BLA is filed.
